Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, South Korea.
Leuk Res. 2010 Sep;34(9):1175-9. doi: 10.1016/j.leukres.2010.02.010. Epub 2010 Mar 5.
Fourteen patients had primary ovarian lymphoma, while eighteen patients had secondary ovarian involvement. There was no significant difference in survival rates between primary and secondary involvement with diffuse large B-cell lymphoma (DLBCL), the most common subtype. The 5-year overall survivals of primary and secondary involvement with DLBCL were 70.0% and 59.3%, respectively. The localized bilateral ovarian involvement showed poorer survival compared to stage III/IV patients with secondary ovarian involvement. Treatment outcomes of secondary ovarian involvement in non-Hodgkin's lymphoma were comparable to those of primary ovarian involvement, suggesting that ovarian involvement does not necessarily predict a worse prognosis for NHL patients.
14 例患者为原发性卵巢淋巴瘤，18 例患者为继发性卵巢受累。弥漫性大 B 细胞淋巴瘤（DLBCL）是最常见的亚型，原发性和继发性受累的存活率之间没有显著差异。原发性和继发性 DLBCL 的 5 年总生存率分别为 70.0%和 59.3%。与继发性卵巢受累的 III/IV 期患者相比，局限性双侧卵巢受累的生存情况更差。非霍奇金淋巴瘤患者的继发性卵巢受累的治疗结果与原发性卵巢受累相似，表明卵巢受累不一定预示 NHL 患者预后更差。
